AL amyloidosis: The last 30 years

References

• Glenner G G, Harbaugh J, Ohms J I, Harada M, Cuatrecasas P. An amyloid protein: the amino-terminal variable fragment of an immunoglobulin light chain. Biochem Biophys Res Comm. 1970; 41: 1287–1289
   PubMed Web of Science ®Google Scholar
• Glenner G G, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 1971; 172: 1150–1151
   PubMed Web of Science ®Google Scholar
• Osserman E F, Takatsuki K, Talal N. The pathogenesis of “amyloidosis”: studies on the role of abnormal gamma globulin fragments of the Bence-Jones type in the pathogenesis of “primary” and “secondary amyloidosis” and the “amyloidosis” associated with plasma cell myeloma. Semin Hematol 1964; 1: 1–85
   Google Scholar
• Isobe T, Osserman E F. Patterns of amyloidosis and their association with plasma cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Eng J Med 1974; 290: 473–477
   PubMed Web of Science ®Google Scholar
• Kyle R A, Bayrd E D. Amyloidosis: review of 236 cases. Medicine 1975; 54: 271–299
   PubMed Web of Science ®Google Scholar
• Kyle R A, Linos A, Beard. Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817–1822
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Skinner M, Benson M D, Cohen A S. Amyloid fibril protein related to immunoglobulin lambda-chains. J Immunol 1975; 114: 1433–1435
   PubMedGoogle Scholar
• Sletten K, Natvig J B, Husby G, Juul J. The complete amino acid sequence of a prototype immunoglobulinlambda light-chain type amyloid fibril protein AR. Biochem J 1981; 195: 561–572
   PubMed Web of Science ®Google Scholar
• Solomon A, Frangione B, Franklin E C. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the Vlambda6 subgroup of human light chains and amyloidosis AL. J Clin Invest 1982; 70: 453–460
   PubMed Web of Science ®Google Scholar
• Ozaki S, Abe M, Wolfenbarger D, Weiss D T, Solomon A. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin Immunol Immunopath 1994; 71: 183–189
   PubMedGoogle Scholar
• Perfetti V, Ubbiali P, Vignarelli M C, Diegoli M, Fasani R, Stoppini M, Lisa A, Mangione P, Obici L, Arbustini E, Merlini G. Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 1998; 91: 2948–2954
   PubMed Web of Science ®Google Scholar
• Hurle M R, Helms L R, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994; 91: 5446–5450
   PubMed Web of Science ®Google Scholar
• Myatt E A, Westholm F A, Weiss D T, Solomon A, Schiffer M, Stevens F J. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci 1994; 91: 3034–3038
   PubMed Web of Science ®Google Scholar
• Kyle R A, Greipp P R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978; 52: 818–827
   PubMed Web of Science ®Google Scholar
• Kyle R A, Greipp P R, Garton J P, Gertz M A. Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med 1985; 79: 708–716
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, Therneau T M. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Eng J Med 1997; 336: 1202–1207
   PubMed Web of Science ®Google Scholar
• Benson M D. Treatment of AL amyloidosis with melphalan, prednisone and colchicine. Arthritis Rheum 1986; 29: 683–687
   PubMedGoogle Scholar
• Skinner M, Anderson J J, Simms R, Falk R, Wang M, Libbey C A, Jones L A, Cohen A S. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–298
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Vosburgh E, Simms R W, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D V, Wright D G, Falk R H, Skinner M. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996; 88: 2801–2806
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Vosburgh E, Falk R H, Sanchorawala V, Reisinger J, Dubrey S, Dember L M, Berk J L, Akpek G, LaValley M, O'Hara C, Arkin C F, Wright D G, Skinner M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and response in 25 patients. Blood 1998; 91: 3662–3670
   PubMed Web of Science ®Google Scholar